This report provides comprehensive information on the therapeutic development for Hepatitis D, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis D and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Hepatitis D Overview
- Therapeutics Development
- Pipeline Products for Hepatitis D - Overview
- Pipeline Products for Hepatitis D - Comparative Analysis
- Hepatitis D - Therapeutics under Development by Companies
- Hepatitis D - Therapeutics under Investigation by Universities/Institutes
- Hepatitis D Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Hepatitis D - Products under Development by Companies
- Hepatitis D - Products under Investigation by Universities/Institutes
- Hepatitis D - Companies Involved in Therapeutics Development
- Alnylam Pharmaceuticals, Inc.
- BioDiem Ltd
- Eiger BioPharmaceuticals, Inc.
- Globeimmune, Inc.
- REPLICor Inc.
- SomaGenics, Inc.
- Spring Bank Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/mbrn8r/hepatitis_d